Suppr超能文献

β-内酰胺酶抑制剂舒巴坦的口服有效酸前药。

Orally effective acid prodrugs of the beta-lactamase inhibitor sulbactam.

作者信息

English A R, Girard D, Jasys V J, Martingano R J, Kellogg M S

机构信息

Pfizer Central Research, Groton, Connecticut 06340.

出版信息

J Med Chem. 1990 Jan;33(1):344-7. doi: 10.1021/jm00163a055.

Abstract

Sulbactam (1) is a beta-lactamase inhibitor with limited oral bioavailability. Lipophilic double-ester prodrug sulbactam pivoxil (2) significantly improves the oral absorption of sulbactam, as does the mutual prodrug double ester sultamicillin (3). We have found that double-ester prodrugs of sulbactam terminating in a carboxyl group (8) also were effective oral-delivery vehicles in rats. Carboxyl-terminated double esters have several potential advantages over their nonionizable lipophilic counterparts, including water solubility, crystallinity, choice of salts for dosage forms, and formation of innocuous byproducts on hydrolysis.

摘要

舒巴坦(1)是一种口服生物利用度有限的β-内酰胺酶抑制剂。亲脂性双酯前药舒巴坦匹伐酯(2)显著提高了舒巴坦的口服吸收,相互前药双酯舒他西林(3)也是如此。我们发现,末端为羧基的舒巴坦双酯前药(8)在大鼠中也是有效的口服给药载体。与不可离子化的亲脂性对应物相比,羧基末端双酯具有几个潜在优势,包括水溶性、结晶性、剂型盐的选择以及水解时形成无害副产物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验